立方制药: 关于取得药品注册证书的公告

Group 1 - The company, Hefei Lifan Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration of Paliperidone Extended-Release Tablets (6mg, 3mg) [1][2] - The drug is classified as a new antipsychotic medication with strong control effects, high affinity, tolerability, and efficacy, designed to release active ingredients slowly for stable blood concentration [2] - Paliperidone Extended-Release Tablets are indicated for the treatment of schizophrenia in adults and adolescents aged 12-17 years (weighing ≥29kg) [2] Group 2 - The approval of the two specifications (6mg, 3mg) will enhance the company's product pipeline in psychiatric medications and improve its market competitiveness [2] - As of the announcement date, there are two imported drug approvals and four domestic drug approvals for this medication in China, indicating a competitive landscape [2]